[up] Up a level
Group by: Item Type | No Grouping
Jump to: Article | Book Section
Number of items: 14.

Article

Curley, P, Giardiello, M, Liptrott, NJ, Dickens, D, Moss, DM, Hobson, J, Savage, AC, McDonald, T, Siccardi, M, Rannard, S and Owen, A (2017) In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line. Journal of Interdisciplinary Nanomedicine, 2 (3). pp. 157-169.

Moss, DM, Domanico, P, Watkinson, M ORCID: https://orcid.org/0000-0003-1877-5667, Seonghee, P, Randolph, R, Wring, S, Rajoli, RKR, Hobson, J, Rannard, S, Siccardi, M and Owen, A (2017) Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate. Antimicrobial Agents and Chemotherapy, 61 (7).

Curley, P, Rajoli, RK, Moss, DM, Liptrott, NJ, Letendre, S, Owen, A and Siccardi, M (2016) Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation. Antimicrobial Agents and Chemotherapy, 61 (1).

Giardiello, M, Liptrott, NJ, McDonald, T, Moss, DM, Siccardi, M, Martin, P, Smith, D, Gurjar, R, Rannard, S and Owen, A (2016) Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. Nature Communications, 7.

Curley, P, Moss, DM, Siccardi, M and Owen, A (2016) Development and Validation of a LC-MS/MS Assay for the Quantification Of Efavirenz In Different Biological Matrices. Bioanalysis, 8 (20). pp. 2125-2134.

Moss, DM, Marzolini, C, Rajoli, RK and Siccardi, M (2015) Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies. Expert Opinion on Drug Metabolism and Toxicology, 11 (8). pp. 1203-1217.

Moss, DM, Liptrott, NJ, Siccardi, M and Owen, A (2015) Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. Frontiers in Pharmacology, 6.

Moss, DM and Siccardi, M (2014) Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling. British Journal of Pharmacology, 171 (17). pp. 3963-3979.

Moss, DM, Curley, P, Shone, A, Siccardi, M and Owen, A (2014) A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. Journal of Antimicrobial Chemotherapy, 69 (12). pp. 3275-3281.

Moss, DM, Liptrott, NJ, Curley, P, Siccardi, M, Back, DJ and Owen, A (2013) Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro. Antimicrobial Agents and Chemotherapy, 57 (11). pp. 5612-5618.

Moss, DM, Siccardi, M, Back, DJ and Owen, A (2013) Predicting intestinal absorption of raltegravir using a population-based ADME simulation. Journal of Antimicrobial Chemotherapy, 68 (7). pp. 1627-1634.

Moss, DM, Siccardi, M, Murphy, M, Piperakis, MM, Khoo, SH, Back, DJ and Owen, A (2012) Divalent metals and pH alter raltegravir disposition in vitro. Antimicrobial Agents and Chemotherapy, 56 (6). pp. 3020-3026.

Moss, DM, Kwan, WS, Liptrott, NJ, Smith, DL, Siccardi, M, Khoo, SH, Back, DJ and Owen, A (2011) Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir. Antimicrobial Agents and Chemotherapy, 55 (2). pp. 879-887.

Book Section

McDonald, T, Siccardi, M, Moss, D, Liptrott, N, Giardiello, M and Owen, A (2015) The Application of Nanotechnology to Drug Delivery in Medicine. In: Nano Engineering: Global Approaches to Health and Safety Issues. Elsevier Health Sciences, Netherlands, pp. 173-224.

This list was generated on Wed Nov 1 01:34:16 2023 UTC.